Dr. Motzer reviews the efficacy and safety data from the KEYNOTE-427 trial.
Stay up to date on practice-changing data in community practice.
Ensuring Response and Tolerable Dose Are Crucial in RCC
During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they modify doses of combination renal cell carcinoma therapies.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
Confronting Prostate Cancer Misinformation in the Digital Age
In an interview, Stacy Loeb, MD, discussed a study analyzing prostate cancer misinformation on social media.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
ClarityDX Prostate Utility Trial Enrolls First Patient
The first patient has been enrolled in a trial evaluating ClarityDX Prostate’s impact on early prostate cancer detection, biopsy reduction, and healthcare efficiency.
Cabozantinib/Nivolumab Efficacy, Safety Considered for Metastatic RCC
During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic renal cell carcinoma.
